Oricell's Ori-C101 CAR-T Therapy Shows Promise in Advanced Liver Cancer Treatment

Hope on the Horizon: Oricell's Breakthrough CAR-T Therapy for Liver Cancer

In a groundbreaking announcement at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2026, Oricell Therapeutics unveiled remarkable clinical data on its leading CAR-T therapy, Ori-C101. This innovative treatment, targeting GPC3, recorded an impressive 66.7% objective response rate (ORR) among patients suffering from late-line refractory hepatocellular carcinoma (HCC). This achievement positions Ori-C101 as a potential frontrunner in the fight against a deadly form of liver cancer, particularly critical as options remain limited for patients who have exhausted standard therapies.

Addressing a Global Health Challenge

Hepatocellular carcinoma continues to pose a significant health threat globally, especially in China where it is responsible for a considerable portion of the over 800,000 fatalities each year due to the disease. Despite advancements in frontline treatment options, patients who fail second-line therapy find themselves with minimal choices, with historical ORRs reported to be under 13%. Oricell’s registrational Phase Ib BEACON study sought to disrupt this dismal status quo.

As of early April 2026, the study included 18 efficacy-evaluable patients, and the results were awe-inspiring. With an overall response rate of 50% noted, the effectiveness soared to 66.7% at the Recommended Phase 2 Dose (RP2D), accompanied by a disease control rate nearing 90%. Notably, the durability of these responses was profound, with one patient achieving a complete response (CR) that persisted for a remarkable span of 24 months.

Safety and Efficacy Combined

Equally as impressive as the efficacy data were the safety results. The therapy exhibited a manageable safety profile, with no occurrences of immune effector cell-associated neurotoxicity syndrome (ICANS) or off-tumor toxicities, and cytokine release syndrome (CRS) remained at controllable grades. This finding increases the feasibility of Ori-C101 for a broader patient population, representing a significant leap forward in CAR-T therapy for solid tumors.

Building on Past Success

The journey towards this pivotal moment began with Oricell's earlier investigator-initiated trial (IIT) data for Ori-C101, also presented at ASCO back in 2021. It indicated a striking partial response in a patient after just one infusion, with target lesions shrinking by 96.1% and alpha-fetoprotein (AFP) levels plummeting by 99.1%. This dramatic improvement established a strong clinical proof of concept that has now been reinforced by the groundbreaking registrational data.

The Power of Innovation: A Unique Technology Framework

Central to the success of Ori-C101 is Oricell's proprietary technology platforms aimed at overcoming the common barriers faced in CAR-T therapies for solid tumors. The multifaceted approach includes:

1. Ori®Ab: An advanced AI-powered antibody discovery platform that houses a vast library of scFv and nanobody sequences. This technology identifies native conformational antigens, including challenging targets, streamlining the antibody discovery cycle from a year to just three months.

2. Ori®Armoring: This innovative platform harnesses tailored